Here are the 10-Q quarterly reports from Palomino Labs Inc (PALX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PALX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PALX filings page.
Palomino Laboratories Inc., a pre-revenue fabless semiconductor company developing microLED-based optoelectronic solutions, reported a net loss of $1,365,034 for the quarter and $2,608,464 for the six months ended June 30, 2026, driven by rising operating expenses.
General and administrative costs reached $1,501,998 and research and development expenses $1,106,876 for the first half of 2026 as the company built out operations, hired staff, and expanded lab activities. There was no revenue in 2025 or 2026.
Cash and cash equivalents increased to $19,444,793 at June 30, 2026, supported by an April 2026 private placement of 4,243,853 shares for gross proceeds of $16,975,412, yielding net proceeds of $14,820,975. Management believes this cash will fund operations for at least one year, though additional capital is expected to be needed over time.
Subsequent to quarter-end, the board approved stock option grants and an all-stock acquisition of Vega Links, Inc. for 4,472,000 shares, and authorized a new California office and technical lease, none of which are yet reflected in the June 30, 2026 financial statements.
Palomino Laboratories Inc. reported first-quarter 2026 results as a pre-revenue, development-stage fabless semiconductor company focused on microLED-based optical interconnects. For the three months ended March 31, 2026, it recorded a net loss of $1,243,430, driven by operating expenses of $1,243,603, including $805,363 in general and administrative costs and $438,240 in research and development.
Cash and cash equivalents were $6,656,641 as of March 31, 2026, with total assets of $7,361,705 and stockholders’ equity of $7,009,735. The company remains pre-revenue but is building out lab equipment and facilities, recording $318,336 of capital spending in the quarter.
Subsequent to quarter-end, Palomino raised an additional $16,975,412 through April 2026 private placements of common stock and warrants, and management believes existing cash plus these proceeds will fund operations for at least one year from the financial statement issuance date. The company expects continued losses as it hires, advances R&D, and protects its intellectual property.